Table 2.

Planned implementation steps and observed outcomes concurrent with the PharmNet study start date.

Intervention stage and planned steps		Outcomes
Launch (on the start date)
	1. Verify the intervention has launched. Reminder post-its are placed in visible areas on the interior of the dispensing location (eg, staff side rather than patient side). Harm reduction referral cards are placed at each checkout for easy access. Yard signs are placed outside the building in visible locations where traffic (vehicle or foot) is common. Scrolling television banner will be enabled to run continuously through the intervention, reading “76.7% of overdoses happen at home. Bystanders who witness an overdose can be effective in reducing overdose mortality. Ask us about how you can save a life with naloxone today!”	Launch verification calls were made by LAE to the intervention pharmacies on November 2, 2022 (the day after launch). Pharmacy 1: The pharmacist who was working that day was a floating pharmacist and transferred LAE to the managing pharmacist. The managing pharmacist reported that the pharmacy “has the supplies and is ready to go.” Pharmacy 2: The pharmacist who was working that day said they had just returned from leave and did not know where the PharmNet intervention materials were in the pharmacy. They reported they would contact the managing pharmacist to find out where the materials were. The pharmacist stated they had watched the training video and were aware of the PharmNet intervention. Pharmacy 3: The pharmacist who was working that day reported they were not aware of receiving the PharmNet materials. They put LAE on hold to check if the supplies were in the pharmacy. They reported to LAE that they could not locate any supplies. Pharmacy 4: The pharmacist who was working that day reported that they had watched the training video and were aware of the PharmNet intervention. They reported that the pharmacy had not received any PharmNet supplies.
	2. Obtain additional details about the launch.	On day 4 of the intervention, LAE called the organizational management team. The primary purpose of the call was to request that they contact intervention pharmacies 2-4 to inform the pharmacists where the PharmNet materials were. LAE asked the managing pharmacist to inform the lead pharmacists at the intervention pharmacies to begin PharmNet if they had not already done so. The managing pharmacist informed the researcher that they would contact the pharmacists over the next few days. Unfortunately, soon after that call, we learned that the managing pharmacist had COVID-19 and was on sick leave. In addition, at least 1 additional lead pharmacist was also on sick leave for COVID-19, and pharmacists from other sites, and (when possible) the managing pharmacist, were often required to staff those roles when no additional staff members were available to do so.